BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis.
2300 Englert Dr.
Durham, NC 27713
BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina’s Research Triangle Park, Cambridge, Massachussetts and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development of biologics across a wide range of disease states. BioAgilytix offers assay development, validation, and sample analysis under non‐GLP, GLP, and GCP, as well as GMP quality control testing (i.e. product release testing, stability testing, etc).
BioAgilytix is a bioanalytical partner to many of the top global pharmaceutical and biotechnology companies. The company also actively supports innovators that are working to progress large molecule breakthroughs, as well as smaller biotechs and emerging biopharma sponsors. Customers continue to choose BioAgilytix as their preferred bioanalytical CRO because of the company’s deep large molecule experience, reputation for quality, unparalleled regulatory track record and their uniquely collaborative approach.
BioAgilytix’s team of highly experienced scientific and QA professionals ensures high quality science, data integrity, and regulatory compliance through all phases of clinical development, and is a trusted partner to many of the top global pharmaceutical and biotech companies. BioAgilytix’s scientific team’s collective experience supporting novel drug development for a wide range of disease areas has made the company a preferred partner for sponsors looking to create more effective biologic therapeutics in these fields. The company’s BPM (bioanalytical project manager) team averages 15+ years of post-school bench experience, with more than 35% comprised of PhD and Masters-level scientists that have been working with leading pharmaceutical and CROs for 10+ years. BioAgilytix’s scientists have supported the development of many key drugs currently on the market, as well as an array of promising clinical candidates, and understand the nuances in scientific, regulatory, and data requirements across disease states – as well as the challenges to anticipate in each phase.
20.12.2021 / Transaction news
Cobepa and BioAgilytix to Continue Highly Successful Partnership
New York, NY; Brussels, Belgium; Munich, Germany – Cobepa S.A. is pleased to announce it has extended its partnership with BioAgilytix (“BioAgilytix” or “the Company”) and entered into a recapitalization of the Company in conjunction with Cinven, a leading international private investment firm focused on building world-class global organizations.
#cobepa #bioagilytix #cinven
17.11.2021 / Portfolio news
BioAgilytix secures significant new investment from global Investor Cinven to fuel continued long-term growth
Investment will provide BioAgilytix with additional resources to invest in core business and drive growth
14.10.2021 / Portfolio news
BioAgilytix Closes Acquisition of Australia-based 360biolabs
Following final government approval, 360biolabs, a BioAgilytix company, adds world-class virology & immunology expertise and LC/MS/MS small molecule capabilities to the company, enabling support of bioanalytical services across all geographies and development stages
#BioAgilytix #acquisition #360biolabs
18.08.2021 / Portfolio news
MicroConstants to Join BioAgilytix Family
Highly complementary transaction strengthens BioAgilytix’s ability to support bioanalytical services across all major therapeutics in development; adds LC/MS/MS capabilities; and expands team of seasoned scientists
#bioagilytix #acquisition #microconstants
16.08.2021 / Portfolio news
BioAgilytix to Purchase Australia-based 360biolabs
Highly complementary transaction will strengthen company's ability to support bioanalytical services across all stages, development capabilities and geographies.
#bioagilytix #acquisition #360biolabs
08.06.2021 / Portfolio news
BioAgilytix Holds Ribbon Cutting to Celebrate Boston Lab Expansion, Additional Jobs and Tech Capabilities
BOSTON, Massachusetts – BioAgilytix, a leading bioanalytical laboratory specializing in large molecule bioanalysis, recently held a ribbon-cutting to celebrate the large-scale expansion of its leading-edge Boston laboratory. Located in the Cambridge, Massachusetts biopharma hub, the expanded CLIA-certified, CAP-accredited laboratory added 21-color flow cytometry and ddPCR, plus additional capacity for more qPCR, ADA/PK and biomarker testing to its already robust preclinical and clinical trials and diagnostic testing capabilities.
14.11.2019 / Portfolio news
BioAgilytix announces acquisition of Boston-based clinical research organization Cambridge Biomedical
Highly complementary transaction strengthens BioAgilytix's ability to support all phases of biologics development; adds to growing cell & gene therapy expertise; increases laboratory capacity; expands team of seasoned bioanalytical scientists; broadens geographic reach.
#Bioagilytix #acquisition #cambridgebiomedical
11.12.2018 / Transaction news
Cobepa completes strategic investment in BioAgilytix
Durham, NC; New York, NY; Brussels, Belgium - BioAgilytix, a leading provider of large molecule bioanalytical testing services, announced today that it has received a strategic investment from Cobepa S.A.
#Cobepa #investment #bioagilytix